These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30236065)

  • 21. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations.
    Schatz U; Arneth B; Siegert G; Siegels D; Fischer S; Julius U; Bornstein SR
    Atheroscler Suppl; 2013 Jan; 14(1):115-22. PubMed ID: 23357152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
    Covic A; Mircescu G
    Nephrol Dial Transplant; 2010 Aug; 25(8):2722-30. PubMed ID: 20190247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
    Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
    Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT
    Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous Iron Use in the Care of Patients with Kidney Disease.
    Macdougall IC
    Clin J Am Soc Nephrol; 2019 Oct; 14(10):1528-1530. PubMed ID: 31175103
    [No Abstract]   [Full Text] [Related]  

  • 27. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
    Pollock RF; Muduma G
    Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
    Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
    J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR
    Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
    Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.
    Macdougall IC; White C; Anker SD; Bhandari S; Farrington K; Kalra PA; McMurray JJV; Murray H; Steenkamp R; Tomson CRV; Wheeler DC; Winearls CG; Ford I;
    Am J Nephrol; 2018; 48(4):260-268. PubMed ID: 30304714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Administration of Intravenous Iron Formulations Induces Complement Activation
    Faria B; Gaya da Costa M; Poppelaars F; Franssen CFM; Pestana M; Berger SP; Daha MR; Gaillard CAJM; Seelen MA
    Front Immunol; 2019; 10():1885. PubMed ID: 31497011
    [No Abstract]   [Full Text] [Related]  

  • 35. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
    Filippatos G; Ponikowski P; Farmakis D; Anker SD; Butler J; Fabien V; Kirwan BA; Macdougall IC; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA;
    Circulation; 2023 May; 147(22):1640-1653. PubMed ID: 37051919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.
    Lichtenstein GR; Onken JE
    Dig Dis Sci; 2018 Nov; 63(11):3009-3019. PubMed ID: 30056562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective cohort study comparing the adverse reactions and efficacy of intravenous iron polymaltose with ferric carboxymaltose for iron deficiency anemia.
    Gilmartin CE; Hoang T; Cutts BA; Leung L
    Int J Gynaecol Obstet; 2018 Jun; 141(3):315-320. PubMed ID: 29498039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
    Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
    Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.